Dana-Farber using new grant to study less-is-more approach to breast cancer

For years, oncologists have aggressively treated an early form of non-invasive breast cancer with surgery and radiation, carving out any part of the breast that was deemed to be a future risk. But with a $13.3 million grant from the Patient-Centered Outcomes Research Institute, Dana-Farber Cancer Institute will study whether such aggressive treatments are necessary for ductal carcinoma in situ (DCIS), and if a wait-and-see approach leads to better outcomes for the patient. Approximately 60,000…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news